Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod PH20 SC for bullous pemphigoid
NL-OMON53428Phase 3Not yet recruiting
- Sponsor
- PPD
- Start
- Nov 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Bullous Pemphigoid (BP) comparing Efgartigimod PH20 SC + oral corticosteroid taper with Placebo PH20 SC + oral corticosteroid taper (2 arms). Planned start Nov 2022; status: not yet recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NL-OMON53428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53428.